Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N + I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214 Meeting Abstract
| Authors: | Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthelemy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Kollmannsberger, C. K.; Gurney, H.; Amin, A.; Grimm, M. O.; Rini, B. I.; Tomita, Y.; McHenry, M. B.; Mekan, S. F.; Escudier, B.; Hammers, H. J. |
| Abstract Title: | Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N + I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214 |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800581 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.581 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 581 -- Source: Wos |
